Subsequently, survival distribution based on stratified analysis of the TMB alone or synergistically with CCL4 revealed that prognostically relevant signatures comprising CCL4 and the TMB might shed new light on promising therapeutic targets in ccRCC. This evidence concerns the gene CCL4 and nonpapillary renal cell carcinoma.